Humanization and characterization of an anti-human TNF-α murine monoclonal antibody.

A murine monoclonal antibody, m357, showing the highly neutralizing activities for human tumor necrosis factor (TNF-α) was chosen to be humanized by a variable domain resurfacing approach. The non-conserved surface residues in the framework regions of both the heavy and light chain variable regions...

Full description

Bibliographic Details
Main Authors: Wei-Chun Chiu, Ya-Ping Lai, Min-Yuan Chou
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21305012/?tool=EBI
id doaj-e4618aec1538484fae9d06c756f68b1c
record_format Article
spelling doaj-e4618aec1538484fae9d06c756f68b1c2021-03-03T19:53:56ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0161e1637310.1371/journal.pone.0016373Humanization and characterization of an anti-human TNF-α murine monoclonal antibody.Wei-Chun ChiuYa-Ping LaiMin-Yuan ChouA murine monoclonal antibody, m357, showing the highly neutralizing activities for human tumor necrosis factor (TNF-α) was chosen to be humanized by a variable domain resurfacing approach. The non-conserved surface residues in the framework regions of both the heavy and light chain variable regions were identified via a molecular modeling of m357 built by computer-assisted homology modeling. By replacing these critical surface residues with the human counterparts, a humanized version, h357, was generated. The humanized h357 IgG(1) was then stably expressed in a mammalian cell line and the purified antibody maintained the high antigen binding affinity as compared with the parental m357 based on a soluble TNF-α neutralization bioassay. Furthermore, h357 IgG(1) possesses the ability to mediate antibody-dependent cell-mediated cytotoxicity and complement dependent cytotoxicity upon binding to cells bearing the transmembrane form of TNF-α. In a mouse model of collagen antibody-induced arthritis, h357 IgG significantly inhibited disease progression by intra-peritoneal injection of 50 µg/mouse once-daily for 9 consecutive days. These results provided a basis for the development of h357 IgG as therapeutic use.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21305012/?tool=EBI
collection DOAJ
language English
format Article
sources DOAJ
author Wei-Chun Chiu
Ya-Ping Lai
Min-Yuan Chou
spellingShingle Wei-Chun Chiu
Ya-Ping Lai
Min-Yuan Chou
Humanization and characterization of an anti-human TNF-α murine monoclonal antibody.
PLoS ONE
author_facet Wei-Chun Chiu
Ya-Ping Lai
Min-Yuan Chou
author_sort Wei-Chun Chiu
title Humanization and characterization of an anti-human TNF-α murine monoclonal antibody.
title_short Humanization and characterization of an anti-human TNF-α murine monoclonal antibody.
title_full Humanization and characterization of an anti-human TNF-α murine monoclonal antibody.
title_fullStr Humanization and characterization of an anti-human TNF-α murine monoclonal antibody.
title_full_unstemmed Humanization and characterization of an anti-human TNF-α murine monoclonal antibody.
title_sort humanization and characterization of an anti-human tnf-α murine monoclonal antibody.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2011-01-01
description A murine monoclonal antibody, m357, showing the highly neutralizing activities for human tumor necrosis factor (TNF-α) was chosen to be humanized by a variable domain resurfacing approach. The non-conserved surface residues in the framework regions of both the heavy and light chain variable regions were identified via a molecular modeling of m357 built by computer-assisted homology modeling. By replacing these critical surface residues with the human counterparts, a humanized version, h357, was generated. The humanized h357 IgG(1) was then stably expressed in a mammalian cell line and the purified antibody maintained the high antigen binding affinity as compared with the parental m357 based on a soluble TNF-α neutralization bioassay. Furthermore, h357 IgG(1) possesses the ability to mediate antibody-dependent cell-mediated cytotoxicity and complement dependent cytotoxicity upon binding to cells bearing the transmembrane form of TNF-α. In a mouse model of collagen antibody-induced arthritis, h357 IgG significantly inhibited disease progression by intra-peritoneal injection of 50 µg/mouse once-daily for 9 consecutive days. These results provided a basis for the development of h357 IgG as therapeutic use.
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21305012/?tool=EBI
work_keys_str_mv AT weichunchiu humanizationandcharacterizationofanantihumantnfamurinemonoclonalantibody
AT yapinglai humanizationandcharacterizationofanantihumantnfamurinemonoclonalantibody
AT minyuanchou humanizationandcharacterizationofanantihumantnfamurinemonoclonalantibody
_version_ 1714825246269243392